Clinical RisksRisks include failure of therapeutic candidates in clinical trials and failure to secure regulatory approval.
Financial PerformanceNet loss was $19.6M, or ($0.49) per share, more than the estimated loss of $12.0M due to foreign exchange, asset depreciation and workforce reduction.
Goodwill ImpairmentFor 4Q24, net loss was $20.5M, or ($0.51) per share, more than the estimated loss of $11.5M due to $12.2M of goodwill impairment.